The Weill Cornell Lymphoma Program has recently opened a new clinical trial for men and women with relapsed or refractory diffuse large B-cell lymphoma, that have either failed or are not eligible for Autologous Stem Cell Transplant. The study sponsor is Bristol-Myers Squibb, and the principal investigator at Weill Cornell is Dr. John Leonard. For more information about the study, please call Amelyn Rodgriguez, RN at (212) 746-1362 or e-mail Amelyn at firstname.lastname@example.org.
- Men and women equal to or greater than 18 years of age
- A performance status of 0 or 1
- Biopsy confirmation of relapsed, refractory DLBCL, or transformed lymphoma (TL) prior to the initiation of study drug
- Prior treatment as defined below:
– Subjects with relapsed or refractory DLBCL or TL after high-dose conditioning chemotherapy and ASCT, or
– Subjects with relapsed or refractory DLBCL or TL after at least 2 prior multi-agent chemotherapy regimens if ASCT ineligible. Ineligibility for ASCT will be determined using local institutional criteria
- Detailed eligibility reviewed when you contact the study team
This clinical trial is testing a drug called Nivolumab (also known as BMS-936558, a monoclonal antibody) as therapy for subjects with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) after failure of autologous stem cell transplant (ASCT). The purpose of this study is to test the effectiveness, safety, and tolerability of the investigational drug Nivolumab.
Subjects enrolled on this study will receive Nivolumab 3 mg/kg intravenously on the start of every 2 week cycle. The study medication may be interrupted, withheld or stopped for different reasons. However, subjects will be asked to follow up periodically for two years after ending treatment.